We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

172 hedge funds and large institutions have $763M invested in Fulcrum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 43 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

269% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 16

230% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $2.69M

54% more capital invested

Capital invested by funds: $496M → $763M (+$267M)

33% more funds holding

Funds holding: 129172 (+43)

25.18% more ownership

Funds ownership: 99.44%124.62% (+25%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

12% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 49

Holders
172
Holders Change
+43
Holders Change %
+33.33%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
59
Increased
43
Reduced
49
Closed
16
Calls
$8.87M
Puts
$2.69M
Net Calls
+$6.18M
Net Calls Change
+$4.66M
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$6.25M -$164K -16,102 -3%
BFM
27
Boothbay Fund Management
New York
$5.85M -$1.64M -160,888 -24%
Jane Street
28
Jane Street
New York
$5.58M +$1.75M +172,230 +54%
Invesco
29
Invesco
Georgia
$4.72M +$2.98M +293,317 +237%
SCM
30
Silverarc Capital Management
Massachusetts
$4.46M +$4.02M +394,650 New
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
$4.44M +$3.99M +392,489 New
Charles Schwab
32
Charles Schwab
California
$4.4M +$564K +55,413 +17%
SCM
33
Sio Capital Management
New York
$4.32M +$3.89M +382,000 New
TI
34
Trexquant Investment
Connecticut
$4.02M +$3.4M +334,532 +1,592%
Goldman Sachs
35
Goldman Sachs
New York
$3.66M -$2.67M -262,472 -45%
Deutsche Bank
36
Deutsche Bank
Germany
$3.25M +$18K +1,767 +0.6%
Bessemer Group
37
Bessemer Group
New Jersey
$3.25M
DCM
38
Driehaus Capital Management
Illinois
$2.75M +$2.48M +243,388 New
Bank of America
39
Bank of America
North Carolina
$2.61M +$854K +83,966 +57%
CCM
40
Catalio Capital Management
New York
$2.28M +$2.05M +201,301 New
NIP
41
Nicholas Investment Partners
California
$2.07M +$1.86M +182,961 New
Wells Fargo
42
Wells Fargo
California
$1.88M +$1.36M +133,888 +412%
Morgan Stanley
43
Morgan Stanley
New York
$1.87M -$796K -78,212 -32%
SAM
44
Simplify Asset Management
Nevada
$1.81M +$778K +76,440 +92%
American Century Companies
45
American Century Companies
Missouri
$1.78M +$55.2K +5,428 +4%
Wellington Management Group
46
Wellington Management Group
Massachusetts
$1.66M -$335K -32,931 -18%
SC
47
SummitTX Capital
Texas
$1.56M +$1.41M +138,143 New
FT
48
Fiduciary Trust
Massachusetts
$1.54M
Barclays
49
Barclays
United Kingdom
$1.5M +$437K +42,925 +48%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$1.32M -$22.9K -2,252 -2%

FULC Hedge Fund Activity: Q4 2025 in Review

172 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2025, worth a combined $763M — up 54% from $496M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new FULC positions and 16 closed out — a net gain of 43 holders — while 43 added to existing stakes and 49 trimmed.

The largest buyer was Braidwell, adding an estimated $28.9M. The largest seller was RA Capital Management, cutting an estimated $42.5M.

  • 172 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2025, up from 129 in Q3 2025.
  • Funds reported $763M of Fulcrum Therapeutics stock for Q4 2025, up 54% quarter-over-quarter.
  • 59 funds opened new Fulcrum Therapeutics positions in Q4 2025 and 16 closed out, a net change of +43 holders.
  • The largest Fulcrum Therapeutics buyer in Q4 2025 was Braidwell, an estimated $28.9M added.
  • The largest Fulcrum Therapeutics seller in Q4 2025 was RA Capital Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q4 2025.